Can treatment with risedronate benefit patients with knee osteoarthritis?: Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 4, 2007, Pages 198-199

  Lohmander, Stefan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RISEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; BONE TURNOVER; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; NONHUMAN; OSTEOLYSIS; OSTEOPHYTE; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 34249854071     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0456     Document Type: Short Survey

References (4)

1. Garnero P (2006) Biochemical markers in osteoarthritis: Will they measure up? Nat Clin Pract Rheumatol 2: 116-117
2. Lohmander LS and Eyre DR (2005) From biomarker to surrogate outcome in osteoarthritis - what are the challenges? J Rheumatol 32: 1142-1143
3. Mazzuca SA et al. (2006) Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 65: 1055-1059
4. Mitchell PG et al. (2006) Pharmacodynamic modulation of bone-derived and cartilage-derived collagen biomarkers in the ovarectomized rat model. Osteoarthr Cartil 14 [suppl B]: S60